3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

Carel W le Roux; Arne Astrup; Ken Fujioka; Frank Greenway; David C W Lau; Luc Van Gaal; Rafael Violante Ortiz; John P H Wilding; Trine V Skjøth; Linda Shapiro Manning; Xavier Pi-Sunyer; Andreas Hamann; Alain Barakat; Matthias Blüher; Thomas Linn; Andrea Mölle; Alexander Segner; Petra Stübler; Regina Tosch-Sisting; Furio Pacini; Ferruccio Santini; Giulio Marchesini; Carlo Maria Rotella; Cecilia Invitti; Roberto Vettor; Silvio Buscemi; Pedro Mezquita Raya; Felipe Casanueva Freijoo; Ramón Gomis de Barbará; Raffaele Carraro; Enrique Romero Bobillo; Carmen de la Cuesta; Csaba Farsang; Albert Csaszar; Barbara Zahorska-Markiewicz; Danuta Pupek-Musialik; Edward Franek; Lucyna Ostrowska; Magdalena Olszanecka-Glinianowicz; Nebojsa Lalic; Dragan Micic; Bernhard Ludvik; Bernhard Paulweber; Rudolf Prager; André Scheen; Luc Van Gaal; Arne Vernon Astrup; Kjeld Hermansen; Sten Madsbad; Aila Rissanen; Sakari Nieminen; Markku Savolainen; Michel Krempf; Monique Romon; Martine Laville; Michel Marre; Reginald Mira; Francis Finucane; Aletha Veenendaal; Frank van Berkum; Solrun Johannsson-Vidarsdóttir; Vivienne Van de Walle; Eelco Meesters; Jøran Hjelmesæth; Tor Ole Klemsdal; Bård Kulseng; Birgit Bach-Kliegel; Kurt Laederach; Lukas Villiger; Alain Golay; Stefan Bilz; Thozhukat Sathyapalan; Stephen Bain; Sudesh Kumar; Carel Wynard Le Roux; Michael E.J. Lean; Barbara McGowan; Tariq Rehman; John Wilding; Gary Wittert; Ian Caterson; Joeseph Proietto; John Prins; Bruno Geloneze Neto; Jorge Luiz Gross; Antonio Roberto Chacra; Alfredo Halpern; Henrique de Almeida Suplicy; Francis Chun Chung Chow; Hemant P Thacker; Manoj Chadha; Hemaraj Chandalia; Ambika Unnikrishnan; Sanjay Kalra; Neeta Deshpande; Minakshi Shunmugavelu; Vaishali Chetan Deshmukh; Maximo Maislos; Gabriella Segal Lieberman; Ilan Shimon; Naftali Stern; Dan Nabriski; Eddy Karnieli; Naim Shehadeh; Guillermo Gonzalez-Galvez; Maria del Rosario Arechavaleta-Granell; Rafael Margarito Violante Ortiz; Guadalupe Morales Franco; Irina Gurieva; Lyudmila Aleksandrovna Suplotova; Ekaterina Troshina; Ludmila Aleksandrovna Ruyatkina; Emma Anatolievna Voychik; Sergey Martsevich; Maria A Startseva; Mary Elizabeth Seeber; Aysha Badat; Graham Ellis; Yuksel Altuntas; Serdar Guler; Ender Ulgen; Tuncay Delibasi; Tony Chetty; Randy Hart; Jeannette Janzen; Isabelle Labonte; David Lau; Joanne Liutkus; Dennis O'Keefe; Raj Padwal; Thomas P.P. Ransom; Richard Tytus; Stanley John Weisnagel; Jay Adler; Keith Aqua; Stephen L Aronoff; Gary W. Bedel; Thomas Craig Blevins; Joe Blumenau; Andrew Peter Brockmyre; Robert S Call; Rafael Canadas; Louis B Chaykin; Kenneth Cohen; Jeffrey Keith Conrow; Matthew G Davis; H Jackson Downey; Steven Richard Drosman; Steven Duckor; H. Frank Farmer; James Farrell; Stephen Fehnel; Matthew Patrick Finneran; Ray Forbes; Alan Forker; Mark Fredrick; Ken Fujioka; Steven Andrew Geller; Santosh Gill; Linda Glaser; Susan Neims Greco; Frank Lyons Greenway; Wayne Harper; Lee Herman; John Hoekstra; Richard Ingebretsen; Rodney Ison; Rajeev K Jain; Roy Kaplan; Steven Richard Kaster; Gregory A Haase; Boris Kerzner; Judith Lee Kirstein; William Koltun; Diane R Krieger; Cora Elizabeth Lewis; Robert Madder; Richard N Marple; Edward J McDermott; Curtis John Mello; Alan B. Miller; Julie Mullen; John Nardandrea; Patrick O'Neil; F. Xavier Pi-Sunyer; Ronald M Pucillo; Chanhaeng Rhee; Scott Redrick; Aaron Pardini; Jeffrey Rothman; Domenica Marie Rubino; Gladstone Sellers; Timothy Smith; William David Byars; Joseph Soufer; Allen Michael Sussman; Kyle Patrick; Erich Lloyd Schramm; Martin Van Cleeff; Saul Reuel Berg; Holly Roxanna Wyatt; James Alan Simon

doi:10.1016/s0140-6736(17)30069-7

3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial

The Lancet ◽

10.1016/s0140-6736(17)30069-7 ◽

2017 ◽

Vol 389 (10077) ◽

pp. 1399-1409 ◽

Cited By ~ 204

Author(s):

Carel W le Roux ◽

Arne Astrup ◽

Ken Fujioka ◽

Frank Greenway ◽

David C W Lau ◽

...

Keyword(s):

Type 2 Diabetes ◽

Risk Reduction ◽

Weight Management ◽

Diabetes Risk ◽

Double Blind Trial ◽

Double Blind ◽

Blind Trial

Download Full-text

Faculty Opinions recommendation of Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725388736.793525626 ◽

2016 ◽

Author(s):

Juan-Carlos Kaski ◽

Amelia Carro

Keyword(s):

Heart Failure ◽

Type 2 Diabetes ◽

Double Blind Trial ◽

Double Blind ◽

Blind Trial

Download Full-text

Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial

The Lancet ◽

10.1016/s0140-6736(14)62225-x ◽

2015 ◽

Vol 385 (9982) ◽

pp. 2067-2076 ◽

Cited By ~ 457

Author(s):

Faiez Zannad ◽

Christopher P Cannon ◽

William C Cushman ◽

George L Bakris ◽

Venu Menon ◽

...

Keyword(s):

Heart Failure ◽

Type 2 Diabetes ◽

Double Blind Trial ◽

Double Blind ◽

Blind Trial

Download Full-text

Metabolic Effects of Replacing Sucrose by Isomaltulose in Subjects With Type 2 Diabetes: A randomized double-blind trial

Diabetes Care ◽

10.2337/dc11-1485 ◽

2012 ◽

Vol 35 (6) ◽

pp. 1249-1251 ◽

Cited By ~ 22

Author(s):

S. Brunner ◽

I. Holub ◽

S. Theis ◽

A. Gostner ◽

R. Melcher ◽

...

Keyword(s):

Type 2 Diabetes ◽

Metabolic Effects ◽

Double Blind Trial ◽

Double Blind ◽

Blind Trial

Download Full-text

Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial

BMJ ◽

10.1136/bmj.b4324 ◽

2009 ◽

Vol 339 (nov09 1) ◽

pp. b4324-b4324 ◽

Cited By ~ 20

Author(s):

S. S Lund ◽

L. Tarnow ◽

M. Frandsen ◽

B. B Nielsen ◽

B. V Hansen ◽

...

Keyword(s):

Type 2 Diabetes ◽

Obese Patients ◽

Double Blind Trial ◽

Double Blind ◽

Blind Trial ◽

Insulin Secretagogue

Download Full-text

Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial

The Lancet ◽

10.1016/s0140-6736(19)32131-2 ◽

2019 ◽

Vol 394 (10208) ◽

pp. 1519-1529 ◽

Cited By ~ 44

Author(s):

David R Matthews ◽

Päivi M Paldánius ◽

Pieter Proot ◽

YannTong Chiang ◽

Michael Stumvoll ◽

...

Keyword(s):

Type 2 Diabetes ◽

Combination Therapy ◽

Double Blind Trial ◽

Newly Diagnosed ◽

Double Blind ◽

Blind Trial ◽

Metformin Monotherapy ◽

Early Combination Therapy

Download Full-text

Efficacy and safety of exenatide as add‐on therapy for patients with type 2 diabetes with an intensive insulin regimen: A randomized double‐blind trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.14225 ◽

2020 ◽

Author(s):

Michael Joubert ◽

Victoria Opigez ◽

Barbora Pavlikova ◽

Laure Peyro Saint Paul ◽

Nathalie Jeandidier ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Regimen ◽

Double Blind Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Blind Trial

Download Full-text

A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes

Diabetes Research and Clinical Practice ◽

10.1016/j.diabres.2017.10.018 ◽

2018 ◽

Vol 138 ◽

pp. 253-261 ◽

Cited By ~ 8

Author(s):

Philip Home ◽

R. Ravi Shankar ◽

Ira Gantz ◽

Carol Iredale ◽

Edward A. O'Neill ◽

...

Keyword(s):

Type 2 Diabetes ◽

Dipeptidyl Peptidase ◽

Double Blind Trial ◽

Efficacy And Safety ◽

Double Blind ◽

Dipeptidyl Peptidase 4 ◽

Blind Trial ◽

Dipeptidyl Peptidase 4 Inhibitor

Download Full-text

Aleglitazar, a dual peroxisome proliferator-activated receptor-α/γ agonist, improves insulin sensitivity, glucose control and lipid levels in people with type 2 diabetes: findings from a randomized, double-blind trial

Diabetes Obesity and Metabolism ◽

10.1111/dom.12620 ◽

2016 ◽

Vol 18 (7) ◽

pp. 711-715 ◽

Cited By ~ 9

Author(s):

A. O. Stirban ◽

M. Andjelkovic ◽

T. Heise ◽

L. Nosek ◽

A. Fischer ◽

...

Keyword(s):

Type 2 Diabetes ◽

Insulin Sensitivity ◽

Glucose Control ◽

Peroxisome Proliferator ◽

Double Blind Trial ◽

Lipid Levels ◽

Double Blind ◽

Peroxisome Proliferator Activated Receptor ◽

Blind Trial

Download Full-text

Addition of Mitiglinide to Pioglitazone Monotherapy Improves Overall Glycemic Control in Japanese Patients with Type 2 Diabetes: A Randomized Double Blind Trial

Endocrine Journal ◽

10.1507/endocrj.k09e-022 ◽

2009 ◽

Vol 56 (5) ◽

pp. 657-664 ◽

Cited By ~ 8

Author(s):

Kohei KAKU ◽

Shun-ichi TANAKA ◽

Hideki ORIGASA ◽

Masatoshi KIKUCHI ◽

Yasuo AKANUMA

Keyword(s):

Type 2 Diabetes ◽

Glycemic Control ◽

Japanese Patients ◽

Double Blind Trial ◽

Double Blind ◽

Blind Trial

Download Full-text

Review for "Effects of DPP ‐4 inhibitor linagliptin versus sulfonylurea glimepiride on systemic haemodynamics in overweight patient with type 2 diabetes: a secondary analysis of an 8‐week randomized controlled double‐blind trial"

10.1111/dom.14107/v2/review2 ◽

2020 ◽

Keyword(s):

Type 2 Diabetes ◽

Secondary Analysis ◽

Double Blind Trial ◽

Overweight Patient ◽

Double Blind ◽

Blind Trial ◽

Randomized Controlled

Download Full-text